Each fall, the ACR/ARHP Annual Meeting takes place in a major U.S. city. More than 15,000 people fill the cavernous halls of the area convention center and nearby hotels to attend scientific and educational sessions, scan the latest data on posters and mingle with colleagues at the annual Presidents’ Reception. What most attendees may not…
Through much of the 20th century, dedicated rheumatic disease units were found in hospitals across the U.S. and countries around the world. In the latter part of the century, this began to change, with hospitals moving toward the consult model of care for rheumatic patients. This change reflects larger shifts in the medical world toward…
Many rheumatology patients have complex conditions and require the added expertise of colleagues in other fields, such as pulmonology, neurology or dermatology. This is even more true when patients with complex care issues are referred to academic medical centers. At such centers, patients often travel hours for an appointment and see more than one provider….
The ACR and the ARHP have a long, rich history of collaboration, spanning close to 25 years together. Our predecessors saw the value of an interprofessional team and having an organization that brings together a vast number of constituencies. The result was these two organizations coming together in 1994 when the ARHP became a division…
Picture this: It’s 3 o’clock in the morning. You can’t sleep. You settle in front of the television to watch a rerun of Dirty Dancing. And then it hits you: Ask your doctor. Even as your eyelids sag, some part of your primitive forebrain snaps to attention. Medical training has turned us all into multitaskers,…
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most used drugs for acute and chronic pain. More than 30 billion doses of NSAIDs are consumed annually from more than 70 million prescriptions.1 Despite their common use, NSAIDs are not free of serious toxicities. In the pre-Vioxx (rofecoxib) era, gastrointestinal toxicity was the primary concern for many NSAIDs….
NETs or LL37-DNA complexes may serve as future targets for SLE therapy. In a recent study, researchers identified a link between neutrophils and NETs, and the activation of self-reactive B cells. Their study describes a neutrophil-B cell interaction unique to lupus…
Making time to advance your career and enjoy family life is no easy task. One busy rheumatologist, educator and mom shares her strategies for success…
NEW YORK (Reuters Health)—Romosozumab improves bone mineral density (BMD) in men with osteoporosis, but safety concerns are holding up its approval in the U.S. Up to 2 million men in the U.S. have osteoporosis, and up to 13 million have osteopenia, researchers note in a report online June 20 in The Journal of Clinical Endocrinology…
Two years ago, veteran leaders of the Pennsylvania Rheumatology Society (PRS)—established 20 years prior—made an important decision to get early career rheumatologists more involved. “We thought younger rheumatologists were under-represented, and we wanted to give them a voice [so they would] better understand a wider range of practice issues our society could address,” explains Alfred…